💡 Join us at #AHPBA26 for an engaging discussion on building, strengthening, & optimizing multidisciplinary #HAItherapy programs. Hear from experts at established HAI therapy centers as they share practical strategies & actionable insights to elevate your team’s capabilities & improve patient outcomes. @AHPBA #MedEd #PatientOutcomes #HealthcareInnovation
Unresectable intrahepatic cholangiocarcinoma (iCCA) remains brutal.
Gem/Cis alone → ~3% 3-year OS.
💥 PUMP-2 (JCO 2025) adds HAIP FUDR + Gem/Cis →
📈 Median OS 22.3 mo
💪 1-yr OS 80%
🔥 3-yr OS 31.5%
Not randomized, but striking signal. Pump trials aren’t easy; select patients, equipoise challenges, complex logistics.
But for liver-confined disease, regional therapy is an essential tool.
I helped launch the @NorthwellHealth Manhattan HAI program to deliver this safely and selectively, results like these remind us why.
@TheGutOncLab@OncoAlert
https://t.co/V2ImjU96dh
We are 15 days out! Still time to register! Join us for a comprehensive CME course on Transradial endovascular interventions! #embolization#pad#obl#io#pae#ufe#stroke
https://t.co/2K8DStFDrZ
Preview one of SIR's Abstracts of the Year! Hear from @SamMouli on the Frontier Study: Preliminary Results of Safety and Feasibility of Yttrium-90 TheraSphere in Recurrent Glioblastoma. Read here: https://t.co/jwxF4GKaGz
#TheraSphereGBM#Y90#FRONTIERstudy#SIR2025 #Abstractoftheyear #Glioblastoma #RecurrentGBM #irad
@SIRspecialists@NorthwesternIR
Extremely pleased to share that we have completed initial enrollment for the #FRONTIERstudy. Thank you to the @NorthwesternIR team and to all of the FRONTIER sites for your dedication to this trial and to advancing treatment of recurrent GBM. Stay tuned for more #Y90 and #TheraSphereGBM updates. Sign up for updates here: https://t.co/FOQ2wPck1c
Thank you @LewandowskiY90 for giving grand rounds about curative intent for HCC! Your insights and expertise are invaluable. The @MountSinaiIR team is grateful for your education and mentorship.
Exciting news! Upon close, the addition of this complementary therapy will allow us to provide treatment options for patients with both #HCC and #mCRC, which impacts 1.4 mil ppl in the US with 150k new cases diagnosed each yr. We look forward to the @InteraOncology team joining BSC and PI!
Webinar: Revolutionizing Embolization - Patient and Case Selection with Obsidio™ Conformable Embolic. This cutting-edge session will explore the first-of-its-kind technology that's reshaping the landscape of embolization procedures.
Register for webinar on Oct 22 https://t.co/ndjWCuf8B1
#embolotherapy #interventionalradiology #embolization #IRads #MedEd #interventionaloncology
This #LiverCancerAwarenessMonth we would like to highlight the amazing work physicians from multiple disciplines have put into the #ROWANstudy. This ground-breaking trial for patients with #HCC could not be possible without the efforts of many physicians throughout the country. Learn more about the #ROWANstudy here: https://t.co/5LYbKDT6f6
#Y90 #Immunotherapy #LiverCancer #LCAM2024 #ClinicalTrials
Safety: https://t.co/IDLT70XUZz
Learn more about how #Obsidio#ConformableEmbolic is being used in practice. Hepatic artery embolization by @TheRealDoctorOs . See the full case library here: https://t.co/2Afpem29qE